Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Tularemia

  • Author: Kerry O Cleveland, MD; Chief Editor: Burke A Cunha, MD  more...
 
Updated: Feb 29, 2016
 

Practice Essentials

Tularemia is an acute, febrile, granulomatous, infectious zoonosis caused by Francisella tularensis, an aerobic, gram-negative, pleomorphic bacillus. F tularensis is one of the most infectious bacterial species known. See the image below.

Eschar on thumb and under thumbnail at the site of Eschar on thumb and under thumbnail at the site of a rabbit bite in a patient with tularemia.

Signs and symptoms

The following are common findings in the various clinical forms of tularemia:

  • Abrupt onset of fever and chills - These symptoms typically last for several days, remit for a brief interval, and then recur
  • Pulse-temperature disassociation [1]
  • Headache
  • Anorexia
  • Malaise and fatigue or prostration
  • Myalgias
  • Cough
  • Vomiting
  • Pharyngitis
  • Abdominal pain
  • Secondary pneumonitis - May occur in 45-83% of patients with the typhoidal form of tularemia

As many as 20% of patients with tularemia have a rash, which may begin as blotchy, macular, or maculopapular and progress to pustular. Erythema nodosum and erythema multiforme are rare.

More specific signs and symptoms are as follows:

  • Ulceroglandular tularemia - Includes painful regional lymphadenopathy and an ulcerated skin lesion
  • Glandular tularemia - Tender lymphadenopathy without evidence of local cutaneous lesions
  • Oculoglandular tularemia - Unilateral conjunctivitis, corneal ulceration, lymphadenopathy, photophobia, lacrimation, lid edema, vision loss (rare)
  • Oropharyngeal tularemia - Stomatitis and exudative pharyngitis or tonsillitis; abdominal pain, nausea, and vomiting; cervical lymphadenopathy; diarrhea; gastrointestinal bleeding
  • Intestinal tularemia - Abdominal pain, vomiting, and diarrhea
  • Pneumonic tularemia - Dry cough, dyspnea, and pleuritic-type chest pain
  • Typhoidal tularemia - Fever, chills, myalgias, malaise, and weight loss

Diagnosis

Serology

The diagnosis of tularemia is usually based on serology results. Tests vary from antibody detection (using latex agglutination or enzyme-linked immunosorbent assay [ELISA] testing) to the examination of a range of polymerase chain reaction (PCR) assay products.[2, 3, 4]

An agglutination titer greater than 1:160 is considered presumptively positive, and treatment may be started if this result is obtained. A second titer, demonstrating a 4-fold increase after 2 weeks, confirms the diagnosis.

Indirect fluorescent antibody testing

Indirect fluorescent antibody testing of suppurative material is rapid and specific. Microscopic examination of tissue and smear specimens is possible using fluorescently labeled antibodies at reference laboratories, possibly providing rapid confirmation of disease.

Histologic studies

Early tularemic lesions may demonstrate areas of focal necrosis surrounded by neutrophils and macrophages. Later, the necrotic areas become surrounded by epithelioid cells and lymphocytes. Caseating granulomata with or without multinucleated giant cells develops in some lesions.

Bacterial culturing

Although F tularensis has been cultured from sputum, pleural fluid, wounds, blood, lymph node biopsy samples, and gastric washings, the yield is extremely low and culturing poses a danger to laboratory personnel.

Imaging

  • Chest radiography - To evaluate for pneumonia; this is indicated in any patient in whom the diagnosis of tularemia is suspected
  • Ultrasonography - To examine lymph nodes for findings suggestive of infection; however, these findings lack specificity

Management

Medical care in tularemia is directed primarily toward antibiotic eradication of F tularensis, with streptomycin being the drug of choice (DOC) for this treatment. Research increasingly supports the use of fluoroquinolones to treat the disease, but clinical experience and in vitro data regarding their efficacy are limited.[5]

Symptomatic and supportive care is applied for accompanying conditions (eg, osteomyelitis, pericarditis, peritonitis) in patients with tularemia, as clinically indicated.

Vaccination

No tularemia vaccine is currently available. A vaccine based on a live strain of the bacterium was previously available but is no longer produced because of concerns about unknown attenuation, safety, and production.

Prevention

  • Avoid tick-infested areas
  • Wear trousers and long-sleeved shirts to avoid tick bites
  • Use tick repellants
  • Frequently inspect the body and clothing for evidence of ticks
  • Avoid exposure to dead or wild mammals and wear gloves if such exposure is necessary; hands should be thoroughly washed afterwards
Next

Background

Tularemia is an acute, febrile, granulomatous, infectious zoonosis caused by Francisella tularensis, an aerobic, gram-negative, pleomorphic bacillus .F tularensis is one of the most infectious bacterial species known, as it can cause illness in humans with exposure to as few as 10-50 organisms. Four major subspecies, or biovars, exist; they differ in virulence and geographic range, with F tularensis biovar tularensis, found primarily in North America, being the most virulent. (See Pathophysiology and Etiology.)

Worldwide, more than 100 species of animals, including mammals, birds, amphibians, and arthropods, host F tularensis. The bacillus, which causes acute infectious illness in humans, may also be found in mud and water. (See Etiology.)

Although tularemia was quite common in the United States before World War II, incidence of the disease began a steady decline in the 1950s, falling to fewer than 0.15 cases per 100,000 population by 1965.[6] As a result, tularemia was removed from the reportable disease list in 1995, although outbreaks and sporadic cases have continued to occur worldwide. The disease was again put on the reportable list in 2000, owing to its potential as a bioweapon.[7, 8] (See Epidemiology.)

While most cases of tularemia in the United States have occurred in the south-central states of Arkansas, Kansas, Missouri, Nebraska, and Oklahoma, the incidence of cases occurring north of these states has been increasing.[9, 10, 11]

Types of tularemia

Some authorities classify tularemia into 2 groups, which include the far more common ulceroglandular form (in which local or regional symptoms and signs predominate) and the more lethal typhoidal form (in which systemic symptoms dominate the clinical picture). More commonly, however, tularemia is divided into the following 7 forms:[12]

  • Ulceroglandular tularemia: Cutaneous ulcer with regional lymphadenopathy
  • Glandular tularemia: Regional lymphadenopathy with no ulcer
  • Oculoglandular tularemia: Conjunctivitis with preauricular lymphadenopathy
  • Oropharyngeal tularemia: Stomatitis, pharyngitis, or tonsillitis with cervical lymphadenopathy
  • Intestinal tularemia: Abdominal pain, vomiting, and diarrhea
  • Pneumonic tularemia: Primary pleuropulmonary disease
  • Typhoidal tularemia: Febrile illness without early localizing signs and symptoms

Each form reflects the mode of transmission. The organism gains access to the host by means of inoculation into skin or mucous membrane or through inhalation or ingestion. (See the image below.)

Ulceroglandular tularemia on an extremity. Courtes Ulceroglandular tularemia on an extremity. Courtesy of Dr Hon Pak.

Biovars of F tularensis

F tularensis is an aerobic, gram-negative, pleomorphic coccobacillus. It is capable of growing within several different cell types, including macrophages, endothelial cells, and hepatocytes.[13, 14]

Four subspecies of F tularensis, all of which have been associated with human disease, have been described, but only the F tularensis biovar tularensis (Jellison type A) and F tularensis biovar holarctica (Jellison type B) are common causes. The 2 forms are serologically identical, differing primarily in their geographic distribution, fermentation reactions, and virulence.

F tularensis biovar tularensis is found predominantly in North America (although cases have been described in Europe) and is an extremely virulent organism. As few as 10-50 organisms may result in disease if inhaled or injected intradermally, although oral ingestion would require as many as 108 organisms for disease to occur.

F tularensis biovar holarctica (also known as F tularensis biovar palearctica) is found primarily in Europe[15] and Asia but has also been identified in cases of tularemia in North America. It is from this less-virulent subspecies that the live virus vaccine is derived. F tularensis biovars novicida and mediasiatica are of low virulence. A Japanese F tularensis biovar holarctica variant, japonica, has been more recently characterized.

Traditionally, Francisella subspecies have been characterized on the basis of biochemical reactions, growth characteristics, and virulence properties. However, biochemical methods for differentiating between the subspecies have been found to be imprecise; newer molecular typing methodology has advanced classification of these organisms.

Bioweapon potential

The species is considered a category A biowarfare agent due to its high infectivity, relative ease of growth and stability in liquid formulation, ease of dissemination, and ability to cause substantial illness and death.[16, 17]

The World Health Organization (WHO) conducted modeling studies in 1970 on the possible use of F tularensis as an aerosolized bioweapon. The WHO estimated that an aerosol dispersal of 50 kg of virulent F tularensis over a metropolitan area with 5 million inhabitants would result in 250,000 incapacitating casualties, including 19,000 fatalities. This dispersal would also result in relapses occurring for many months after the initial exposure and the potential to establish enzootic reservoirs of tularemia in wild animals, leading to possible subsequent outbreaks.

A subsequent modeling study found that mitigation strategies will have to depend on the size of the release, the stockpile level of antibiotics, and the speed of antibiotic distribution. As previously mentioned, due to concerns regarding its potential use as a biowarfare agent, tularemia, which had been taken off the list of reportable diseases in 1995, was reinstated on the list in 2000.[18, 19]

Patient education

Direct patient education at limiting tick and deer fly exposure. If the patient hunts, stress the importance of learning contact precautions and good hygiene for handling rabbits and other wild animals.

For patient education information, see Ticks.

Previous
Next

Pathophysiology

The cell wall of F tularensis possesses high levels of fatty acids, and wild strains have an electron-transparent, lipid-rich capsule. Loss of this capsule may result in loss of serum resistance and virulence; however, the capsule exhibits no innate immunogenicity or toxicity.

A subcutaneous inoculum of 10 organisms is sufficient to induce disease, whereas an inhalational exposure of 25 organisms may cause a severely debilitating or fatal disease. Over the first 3-5 days after cutaneous exposure, the organism multiplies locally and a papule forms.

During the next 2-4 days, the site ulcerates. Organisms spread from the entry site to regional lymph nodes and may disseminate lympho-hematogenously to involve multiple organs. Pulmonary findings may be primary after direct inhalation of aerosolized bacteria or may be present in up to half of all tularemia cases from hematogenous spread (secondary pneumonia). Patients are most likely bacteremic at this time, although this is not usually detected.

Immune response

Infection produces an acute inflammatory response initially involving local macrophages, neutrophils, and fibrin. T lymphocytes, epithelioid cells, and giant cells then migrate into local necrotic tissue.[20] As the area of necrosis expands, thrombosis of adjacent arteries and veins may occur. Granulomas develop, which may caseate and be mistaken for tuberculosis, and necrotic foci may coalesce to form abscesses. These changes occur in infected sites and have been demonstrated on autopsy in lymph nodes, the liver, the spleen, bone marrow, and the lungs.[21] F tularensis may remain viable for prolonged periods. They may remain viable in the tissues, where they cause infection.

During the second to third week of Francisella infection, humoral immunity develops against the bacterium's carbohydrate antigens. Agglutinating immunoglobulin M (IgM), IgG, and IgA antibodies are seen at this time.[14, 22] Opsonizing IgG and IgM antibodies are also produced; these act in conjunction with complement (C3).

B-cell ̶ deficient mice have been shown to have impaired clearance of organisms after primary infection with the less virulent vaccine strain of Francisella.[23] In addition, alpha/beta T-cell ̶ dependent immunity, involving either CD4+ or CD8+ T cells and directed against protein antigens, has been demonstrated to be necessary for effective eradication of Francisella.[13, 14]

It has also been found that in humans, tularemia antigens, whether introduced by natural exposure or vaccination, elicit a vigorous and long-lasting response by memory T cells (TM cells). Some of these TM cells have lytic potential, and they demonstrate the ability to enter intestinal mucosal and nonmucosal lung sites.[24]

Preformed molecules on the surface of Francisella trigger rearrangements of the host cell cytoskeleton. Macrophage complement receptors interact with complement factor C3 fixed by molecules on the bacterial cell surface, and bacteria are internalized by looping phagocytosis.

Immediately after phagocytosis, the bacteria are housed in a nonacidified phagosome. Bacteria may degrade the phagosomal membrane and escape into the cytoplasm, where they actively multiply. This can lead to cell death and liberation of bacteria. In rodent macrophages, bacterial survival has been shown to be associated with failure of phagosome-lysosome fusion, phagosome acidification, and utilization of host iron.[25]

It has also been found that a lack of CD14 on human dendritic cells in the lung, or the existence of just minimal amounts of it, appears to contribute to F tularensis evasion of the host’s immune response.[26]

Interferon gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) activate macrophages to kill Francisella through the production of reactive nitrogen products such as nitric oxide (NO),[27] while neutrophils and mononuclear cells have been demonstrated to accumulate at infected liver foci and lyse Francisella -containing hepatocytes, releasing organisms from their relatively protected, sequestered environment.[28]

The ability of F tularensis to impair phagocyte function and survive in infected cells is central to its virulence. This intracellular life cycle has been shown to be related to the tightly regulated expression of a series of genes.[29, 30]

In the unique environment of the lung, oxygen-dependent neutrophil killing of wild virulent strains appears to be only partially effective.[31] Shortly after inhalation, Francisella are found inside cells that typically act as cytokine-producing first responders to infection, including airway macrophages and alveolar epithelial cells. Mouse experiments demonstrate lack of production of pro-inflammatory cytokines, including interleukin 12p40 (IL-12p40), TNF, IL-6, and IL-1 alpha. The exact mediators responsible for immunosuppression remain unclear; however, immunomodulatory factors, such as transforming growth factor-beta (TGF-beta) and prostaglandin E2 (PGE2), may be actively involved.

Approximately 48-72 hours postinfection, a number of cytokines and chemokines, such as IFN-gamma and TNF, are upregulated, and levels of proinflammatory mediators, such as RANTES (regulated on activation, normal T cell expressed and secreted), IL-6, and IL-1 beta, are detected. Unfortunately, the lung may contain more than 108 colony-forming units (CFU) of F tularensis, and this upregulation may be too late to prevent death.[13, 32] This late "cytokine storm," similar to that demonstrated in other instances of severe bacterial sepsis, may actually prove harmful to the host, causing capillary leakage, tissue injury, and lethal organ failure.[33, 34]

The incubation period for tularemia depends on the size of the inoculum, but ranges from 1-21 days (average 2-6 days). Individuals with tularemia may be asymptomatic or acutely septic with rapid death. Six clinical forms of tularemia have been identified. Each form is influenced by factors related to the host, organism, route of transmission, and host entry site.

Previous
Next

Etiology

As previously mentioned, 4 subspecies of F tularensis have been described. Although all of them have been associated with human disease, however, only the F tularensis biovar tularensis (Jellison type A) and F tularensis biovar holarctica (Jellison type B) are common causes. The 2 forms are serologically identical, differing primarily in their geographic distribution, fermentation reactions, and virulence.

F tularensis biovar tularensis is generally found in North American rabbits and ticks and causes severe disease in humans. An inoculum of 10 organisms subcutaneously is sufficient to induce disease, while an inhalational exposure of only 25 organisms may cause disease.

F tularensis biovar holarctica is found primarily in Asian and European rodents and results in a milder form of disease in humans.

Methods of transmission include inhalation, ingestion, contact with an infected animal, and vector-associated exposure.

Transmission

Human-to-human spread of tularemia is not thought to occur. Transmission of disease to humans most often results from an insect bite or contact with contaminated animals or animal products.[35, 36] Thorough cooking of meat before consumption is believed to lessen the likelihood of transmission.

Transmission has also been described via ingestion of or contact with contaminated water, exposure to contaminated mud, animal bites,[37, 38] and exposure to aerosolized water droplets or dust from contaminated soil or grains.

Francisella has been shown to survive for prolonged periods of time in frozen water, mud, and animal carcasses.[8] Carnivores, such as domestic cats, may transiently harbor Francisella in their mouths or on their claws after killing or feeding on infected prey, regardless of whether they have actually become infected. Cases have developed in laboratory workers, who should be notified in advance to safely handle specimens when tularemia is suspected.

Animal hosts

F tularensis is capable of infecting hundreds of different invertebrate, aquatic, and terrestrial vertebrate species, including lagomorphs, rodents, ticks, mosquitos, and flies. In any geographic region, usually no more than a dozen mammals are important to its ecology. However, the overall ecology of F tularensis remains poorly characterized, particularly transmission cycles and specific differences between the 4 subspecies.[39, 40]

Lagomorphs, including Sylvilagus and Lepus species, have been historically recognized as common sources of transmission (hence the common names wild hare disease and rabbit skinners' disease for tularemia). In North America, squirrels, muskrat, beavers, and voles have also been identified as natural reservoirs of F tularensis. In the former Soviet Union, in addition to hares, animal hosts include hamsters, voles, water rats and mice.[37]

Tularemia has been recovered from over 54 species of arthropods.[41] Blood-feeding flies and arthropods are the most important vectors for tularemia in the United States. Biting flies, such as deer flies (Chrysops discalis), are the predominant vectors in the far western states, while ticks, primarily Amblyomma americanum, Dermacentor andersoni, and D variabilis, are important vectors from the Rocky Mountains eastward. In Northern Europe and the former Soviet Union, mosquitos serve as the most important insect vector.

Ticks are a particularly important reservoir and vector because at least 13 different species have been found to be infected with F tularensis. In addition, vertical transmission of the bacterium transovarially has been demonstrated. F tularensis may be present in tick feces or saliva and can be inoculated directly or indirectly into the bite wound.

Specific etiologies

Ulceroglandular form

This form occurs in 70-80% of cases. The organism enters through a scratch, abrasion, or tick or insect bite and spreads via the proximal lymphatic system. Within the ulceroglandular form, more differentiation exists. A subcutaneous inoculum of as few as 10 organisms can cause disease. (See the image below.)

Ulceroglandular type of tularemia on the hand. Cou Ulceroglandular type of tularemia on the hand. Courtesy of Dr Hon Pak.

Glandular form

This form of the disease is rare. No ulcer is present, and the organism is presumed to have gained access to the lymphatic system and/or bloodstream through clinically unapparent abrasions.

Oculoglandular form

In this form of tularemia, which makes up 1% of cases, the organism enters through the conjunctiva from either a splash of infected blood or rubbing the eyes after contact with infectious materials (eg, blood from a rabbit carcass).

Oropharyngeal form

This form of the disease, which is also rare, occurs after ingestion of undercooked rabbit meat containing the organism or consumption of contaminated water.

Pneumonic form

This uncommon form of tularemia occurs when the organism is inhaled via aerosols of water or dust from soil, grains, or pelts or arises secondary to hematogenous spread of the bacterium. It is observed in laboratory workers and occasionally occurs naturally. Pneumonia also occurs in 10-15% of patients with ulceroglandular tularemia and in 50% of those with typhoidal tularemia. The mortality rate can reach 60% if untreated.

Typhoidal (or septicemic) form

This form, which occurs in 10-15% of cases, is more severe than the others and often includes pneumonia. Ingestion may be the mode of transmission; in most cases, however, the portal of entry remains unknown.

Previous
Next

Epidemiology

Tularemia is widely distributed; however, it is found largely in the northern hemisphere from 30-71° north latitude. The disease is most commonly described in the western and south-central regions of the United States and in continental Europe and Asia.

Occurrence in the United States

A few hundred cases of tularemia are reported annually in the United States, Most reported cases occur in Arkansas, Tennessee, Texas, Oklahoma, Kansas, Utah, and Missouri.

In the past, tularemia infections reportedly occurred more frequently during the cold-weather months (eg, rabbit-associated disease); however, the infections are now being reported more frequently during warm-weather months (eg, tick-associated disease).

Approximately 200 cases of tularemia are reported annually in the United States, although many cases are probably undiagnosed, misdiagnosed, or unreported. The disease has been reported in all states except Hawaii.

Transmission of tularemia was previously most frequent from June through August and in December. The summer peak was thought to be due to insect bites, while the winter peak was attributed to hunting-associated cases. Peak reporting now occurs in late spring and early summer.[6] From 1990-2000, 56% of cases reported in the United States were from Arkansas, Missouri, Oklahoma, and South Dakota, with high numbers of cases also reported in Massachusetts, Kansas, and Montana.[25] High incidence rates among indigenous Alaskans and Native Americans have also been reported.[6, 42]

Occupations and avocations associated with an increased risk of tularemia include the following:

  • Laboratory work
  • Veterinary practice
  • Farming
  • Landscaping
  • Working with sheep
  • Hunting and trapping
  • Meat handling

International occurrence

Tularemia occurs throughout the Northern Hemisphere, except for in the United Kingdom. Cases have been reported in the United States, the former Soviet Union, Japan, Canada, Mexico, and Europe.[35, 40, 42] Tularemia has not been reported in Africa and South America.

Sex- and age-related demographics

Although both sexes are equally susceptible to tularemia, males are more frequently affected than females. This primarily results from increased exposure to specific activities (eg, hunting and skinning animals) and increased occupational vulnerability among males.

People of all ages are susceptible to the tularemia; however, young to middle-aged people are more likely to participate in activities that predispose them to exposure.[6]

Previous
Next

Prognosis

Untreated tularemia has a mortality rate of 5-15%; if treated, the disease carries a mortality rate of 1-3%. The mortality rate is 2-3 times higher in patients with typhoidal tularemia than in those with other forms.

Other factors associated with increased mortality include elevated creatine kinase levels, renal failure, and other serious comorbidities, as well as late diagnosis. The mortality rate also depends on the subspecies involved; F tularensis biovar tularensis is significantly more virulent than the others and is responsible for almost all reported deaths.

Previous
Next

Complications

Complications of tularemia include the following:

  • Pneumonia
  • Lung abscess
  • Respiratory failure, including possible acute respiratory distress syndrome (ARDS)
  • Rhabdomyolysis
  • Renal failure with possible hemodialysis
  • Hemoptysis
  • Meningitis
  • Endocarditis
  • Suppurative lymphadenitis
  • Pericarditis
  • Peritonitis
  • Appendicitis
  • Perisplenitis
  • Osteomyelitis
  • Guillain-Barré syndrome
  • Hepatitis
  • Sepsis
Previous
 
 
Contributor Information and Disclosures
Author

Kerry O Cleveland, MD Professor of Medicine, University of Tennessee College of Medicine; Consulting Staff, Department of Internal Medicine, Division of Infectious Diseases, Methodist Healthcare of Memphis

Kerry O Cleveland, MD is a member of the following medical societies: American College of Physicians, Society for Healthcare Epidemiology of America, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Coauthor(s)

Gregory J Raugi, MD, PhD Professor, Department of Internal Medicine, Division of Dermatology, University of Washington at Seattle School of Medicine; Chief, Dermatology Section, Primary and Specialty Care Service, Veterans Administration Medical Center of Seattle

Gregory J Raugi, MD, PhD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Michael Gelfand, MD, FACP Chief, Professor, Department of Internal Medicine, Division of Infectious Diseases, Methodist Healthcare of Memphis, University of Tennessee Health Science Center College of Medicine

Michael Gelfand, MD, FACP is a member of the following medical societies: American College of Physicians, American Medical Association, American Society for Microbiology, Infectious Diseases Society of America, Southern Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Acknowledgements

Richard B Brown, MD, FACP Chief, Division of Infectious Diseases, Baystate Medical Center; Professor, Department of Internal Medicine, Tufts University School of Medicine

Richard B Brown, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Chest Physicians, American College of Physicians, American Medical Association, American Society for Microbiology, Infectious Diseases Society of America, and Massachusetts Medical Society

Disclosure: Nothing to disclose.

Dan Danzl, MD Chair, Department of Emergency Medicine, Professor, University of Louisville Hospital

Dan Danzl, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, Kentucky Medical Association, Society for Academic Emergency Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Jonathan A Edlow, MD Associate Professor of Medicine, Department of Emergency Medicine, Harvard Medical School; Vice Chairman, Department of Emergency Medicine, Beth Israel Deaconess Medical Center

Jonathan A Edlow, MD is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Jon Mark Hirshon, MD, MPH Associate Professor, Department of Emergency Medicine, University of Maryland School of Medicine

Jon Mark Hirshon, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Public Health Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Kelly Maurelus, MD Resident Physician, Department of Emergency Medicine, Kings County Hospital, State University of New York Downstate

Kelly Maurelus, MD, is a member of the following medical societies: American Medical Student Association/Foundation and Student National Medical Association

Disclosure: Nothing to disclose.

Suzanne Moore Shepherd, MD, MS, DTM&H, FACEP, FAAEM Professor of Emergency Medicine, Education Officer, Department of Emergency Medicine, Hospital of the University of Pennsylvania; Director of Education and Research, PENN Travel Medicine; Medical Director, Fast Track, Department of Emergency Medicine

Suzanne Moore Shepherd, MD, MS, DTM&H, FACEP, FAAEM is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American Society of Tropical Medicine and Hygiene, International Society of Travel Medicine, Society for Academic Emergency Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

William H Shoff, MD, DTM&H Director, PENN Travel Medicine; Associate Professor, Department of Emergency Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine

William H Shoff, MD, DTM&H is a member of the following medical societies: American College of Physicians, American Society of Tropical Medicine and Hygiene, International Society of Travel Medicine, Society for Academic Emergency Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Richard H Sinert, DO Associate Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, Research Director, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center

Richard H Sinert, DO is a member of the following medical societies: American College of Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Russell W Steele, MD Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Robert W Tolan Jr, MD Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine

Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility

Disclosure: Novartis Honoraria Speaking and teaching

Mark R Wallace, MD, FACP, FIDSA Clinical Professor of Medicine, Florida State University College of Medicine; Head of Infectious Disease Fellowship Program, Orlando Regional Medical Center

Mark R Wallace, MD, FACP, FIDSA is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Tropical Medicine and Hygiene, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Evans ME, Gregory DW, Schaffner W, McGee ZA. Tularemia: a 30-year experience with 88 cases. Medicine (Baltimore). 1985 Jul. 64(4):251-69. [Medline].

  2. Gelfand MS, Slade W, Abolnik IZ. Tularemia serology: Differentiating true-positive and false-positive titers. Inf Dis Clin Pract. 1992. 1:105-8.

  3. Tärnvik A, Chu MC. New approaches to diagnosis and therapy of tularemia. Ann N Y Acad Sci. 2007 Jun. 1105:378-404. [Medline].

  4. Matero P, Hemmilä H, Tomaso H, Piiparinen H, Rantakokko-Jalava K, Nuotio L, et al. Rapid field detection assays for Bacillus anthracis, Brucella spp., Francisella tularensis and Yersinia pestis. Clin Microbiol Infect. 2011 Jan. 17(1):34-43. [Medline].

  5. [Guideline] Finnish Medical Society Duodecim. Tularaemia. EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; Apr 27 2008. [Full Text].

  6. Tularemia--United States, 1990-2000. MMWR Morb Mortal Wkly Rep. 2002 Mar 8. 51(9):181-4. [Medline].

  7. Feldman KA, Enscore RE, Lathrop SL, Matyas BT, McGuill M, Schriefer ME, et al. An outbreak of primary pneumonic tularemia on Martha's Vineyard. N Engl J Med. 2001 Nov 29. 345(22):1601-6. [Medline].

  8. Reintjes R, Dedushaj I, Gjini A, Jorgensen TR, Cotter B, Lieftucht A, et al. Tularemia outbreak investigation in Kosovo: case control and environmental studies. Emerg Infect Dis. 2002 Jan. 8(1):69-73. [Medline]. [Full Text].

  9. Adams D, Fullerton K, Jajosky R, Sharp P, Onweh D, Schley A, et al. Summary of Notifiable Infectious Diseases and Conditions - United States, 2013. MMWR Morb Mortal Wkly Rep. 2015 Oct 23. 62 (53):1-122. [Medline].

  10. Pedati C, House J, Hancock-Allen J, Colton L, Bryan K, Ortbahn D, et al. Notes from the Field: Increase in Human Cases of Tularemia - Colorado, Nebraska, South Dakota, and Wyoming, January-September 2015. MMWR Morb Mortal Wkly Rep. 2015 Dec 4. 64 (47):1317-8. [Medline].

  11. Centers for Disease Control and Prevention (CDC). Tularemia - United States, 2001-2010. MMWR Morb Mortal Wkly Rep. 2013 Nov 29. 62 (47):963-6. [Medline].

  12. CDC. Tularemia (Francisella tularensis) 1999 Case Definition. cdc.gov. Available at http://wwwn.cdc.gov/nndss/conditions/tularemia/case-definition/1999/. Accessed: February 27, 2016.

  13. Tarnvik A, Berglund L. Tularemia. Eur Respir J. 2003. 21:361-73.

  14. Yee D, Rhinehart-Jones TR, Elkins KL. Loss of either CD4+ or CD8+ T cells does not affect the magnitude of protective immunity to an intracellular pathogen, Francisella tularensis strain LVS. J Immunol. 1996 Dec 1. 157(11):5042-8. [Medline].

  15. Maurin M, Pelloux I, Brion JP, Del Banõ JN, Picard A. Human tularemia in France, 2006-2010. Clin Infect Dis. 2011 Nov. 53(10):e133-41. [Medline].

  16. Pohanka M, Skládal P. Bacillus anthracis, Francisella tularensis and Yersinia pestis. The most important bacterial warfare agents - review. Folia Microbiol (Praha). 2009. 54(4):263-72. [Medline].

  17. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Tularemia as a biological weapon: medical and public health management. JAMA. 2001 Jun 6. 285(21):2763-73. [Medline].

  18. Egan JR, Hall IM, Leach S. Modeling inhalational tularemia: deliberate release and public health response. Biosecur Bioterror. 2011 Dec. 9(4):331-43. [Medline]. [Full Text].

  19. Chaudhury S, Abdulhameed MD, Singh N, Tawa GJ, D'haeseleer PM, Zemla AT, et al. Rapid Countermeasure Discovery against Francisella tularensis Based on a Metabolic Network Reconstruction. PLoS One. 2013. 8(5):e63369. [Medline]. [Full Text].

  20. Hepburn MJ, Friedlander AM, Dembek ZF. Tularemia. Textbook of Military Medicine: Medical Aspects of Biological Warfare. Washington, DC: Borden Institute, US Army; 2008. 167-84.

  21. Geyer SJ, Burkey A, Chandler FW. Tularemia. Connor DH. Pathology of Infectious Diseases. Stamford, CT: Appleton & Lange; 1997. 869-73.

  22. Koskela P, Salminen A. Humoral immunity against Francisella tularensis after natural infection. J Clin Microbiol. 1985 Dec. 22(6):973-9. [Medline]. [Full Text].

  23. Elkins KL, Bosio CM, Rhinehart-Jones TR. Importance of B cells, but not specific antibodies, in primary and secondary protective immunity to the intracellular bacterium Francisella tularensis live vaccine strain. Infect Immun. 1999 Nov. 67(11):6002-7. [Medline]. [Full Text].

  24. Salerno-Goncalves R, Hepburn MJ, Bavari S, Sztein MB. Generation of heterogeneous memory T cells by live attenuated tularemia vaccine in humans. Vaccine. 2010. 28:195-206.

  25. Tularemia--Oklahoma, 2000. MMWR Morb Mortal Wkly Rep. 2001 Aug 24. 50(33):704-6. [Medline].

  26. Chase JC, Bosio CM. The presence of CD14 overcomes evasion of innate immune responses by virulent Francisella tularensis in human dendritic cells in vitro and pulmonary cells in vivo. Infect Immun. 2010 Jan. 78(1):154-67. [Medline]. [Full Text].

  27. Green SJ, Nacy CA, Schreiber RD, Granger DL, Crawford RM, Meltzer MS, et al. Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect Immun. 1993 Feb. 61(2):689-98. [Medline]. [Full Text].

  28. Conlan JW, North RJ. Early pathogenesis of infection in the liver with the facultative intracellular bacteria Listeria monocytogenes, Francisella tularensis, and Salmonella typhimurium involves lysis of infected hepatocytes by leukocytes. Infect Immun. 1992 Dec. 60(12):5164-71. [Medline]. [Full Text].

  29. Meibom KL, Barel M, Charbit A. Loops and networks in control of Francisella tularensis virulence. Future Microbiol. 2009 Aug. 4(6):713-29. [Medline].

  30. Johansson A, Göransson I, Larsson P, Sjöstedt A. Extensive allelic variation among Francisella tularensis strains in a short-sequence tandem repeat region. J Clin Microbiol. 2001 Sep. 39(9):3140-6. [Medline]. [Full Text].

  31. Conlan JW, KuoLee R, Shen H, Webb A. Different host defences are required to protect mice from primary systemic vs pulmonary infection with the facultative intracellular bacterial pathogen, Francisella tularensis LVS. Microb Pathog. 2002 Mar. 32(3):127-34. [Medline].

  32. Cowley SC. Editorial: Proinflammatory cytokines in pneumonic tularemia: too much too late?. J Leukoc Biol. 2009 Sep. 86(3):469-70. [Medline].

  33. Sharma J, Li Q, Mishra BB, Pena C, Teale JM. Lethal pulmonary infection with Francisella novicida is associated with severe sepsis. J Leukoc Biol. 2009 Sep. 86(3):491-504. [Medline]. [Full Text].

  34. Washburn AM, Fullilove RE, Fullilove MT, Keenan PA, McGee B, Morris KA, et al. Acupuncture heroin detoxification: a single-blind clinical trial. J Subst Abuse Treat. 1993 Jul-Aug. 10(4):345-51. [Medline].

  35. Hauri AM, Hofstetter I, Seibold E, Kaysser P, Eckert J, Neubauer H, et al. Investigating an airborne tularemia outbreak, Germany. Emerg Infect Dis. 2010 Feb. 16(2):238-43. [Medline]. [Full Text].

  36. Djordjevic-Spasic M, Potkonjak A, Kostic V, Lako B, Spasic Z. Oropharyngeal tularemia in father and son after consumption of under-cooked rabbit meat. Scand J Infect Dis. 2011 Dec. 43(11-12):977-81. [Medline].

  37. Tularemia associated with a hamster bite--Colorado, 2004. MMWR Morb Mortal Wkly Rep. 2005 Jan 7. 53(51):1202-3. [Medline].

  38. Yuen JC, Malotky MV. Francisella tularensis osteomyelitis of the hand following a cat bite: a case of clinical suspicion. Plast Reconstr Surg. 2011 Jul. 128(1):37e-9e. [Medline].

  39. Keim PS, Wagner DM. Humans and evolutionary and ecological forces shaped the phylogeography of recently emerged diseases. Nat Rev Microbiol. 2009 Nov. 7(11):813-21. [Medline]. [Full Text].

  40. Rydén P, Björk R, Schäfer ML, Lundström JO, Petersén B, Lindblom A, et al. Outbreaks of tularemia in a boreal forest region depends on mosquito prevalence. J Infect Dis. 2012 Jan 15. 205(2):297-304. [Medline]. [Full Text].

  41. Eisen RJ, Gage KL. Transmission of flea-borne zoonotic agents. Annu Rev Entomol. 2012. 57:61-82. [Medline].

  42. Hansen CM, Vogler AJ, Keim P, Wagner DM, Hueffer K. Tularemia in Alaska, 1938 - 2010. Acta Vet Scand. 2011 Nov 18. 53:61. [Medline]. [Full Text].

  43. Stoecker WV, Calcara DA, Malters JM, Clonts M, Everett ED. Tick-borne febrile illnesses lacking specific symptoms. Mo Med. 2009 Jul-Aug. 106(4):304-8. [Medline].

  44. Hornick R. Tularemia revisited. N Engl J Med. 2001 Nov 29. 345(22):1637-9. [Medline].

  45. Fredricks DN, Remington JS. Tularemia presenting as community-acquired pneumonia. Implications in the era of managed care. Arch Intern Med. 1996 Oct 14. 156(18):2137-40. [Medline].

  46. Jensen WA, Kirsch CM. Tularemia. Semin Respir Infect. 2003 Sep. 18(3):146-58. [Medline].

  47. Francis E. A summary of the present knowledge of Tularemia. Medicine. 1928. 7:411-32.

  48. Ozsürekci Y, Ceyhan M, Celik M, Kara A, Cengiz AB, Ozgen-Mocan B. Suppurative cervical adenopathy and pharyngeal mass due to tularemia unresponsive to medical treatment. Turk J Pediatr. 2011 Sep-Oct. 53(5):554-7. [Medline].

  49. Thomas LD, Schaffner W. Tularemia pneumonia. Infect Dis Clin North Am. 2010 Mar. 24(1):43-55. [Medline].

  50. Belhassen-Garcia M, Velasco-Tirado V, Alvela-Suárez L, Fraile-Alonso Mdel C, Carpio-Pérez A, Pardo-Lledias J. Cavitary pneumonia and skin lesions. Respir Care. 2012 Mar. 57(3):457-9. [Medline].

  51. van de Beek D, Steckelberg JM, Marshall WF, Kijpittayarit S, Wijdicks EF. Tularemia with brain abscesses. Neurology. 2007 Feb 13. 68(7):531. [Medline].

  52. Mitchell LA, Bradsher RW Jr, Paden TC, Malak SF, Warmack TS, Nazarian SM, et al. Tularemia induced bilateral optic neuritis. J Ark Med Soc. 2006 Mar. 102(9):246-9. [Medline].

  53. Karabay O, Kilic S, Gurcan S, Pelitli T, Karadenizli A, Bozkurt H, et al. Cervical lymphadenitis: tuberculosis or tularaemia?. Clin Microbiol Infect. 2013 Feb. 19(2):E113-7. [Medline].

  54. [Guideline] Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of america. Clin Infect Dis. 2014 Jul 15. 59(2):e10-52. [Medline].

  55. Svensson K, Granberg M, Karlsson L, Neubauerova V, Forsman M, Johansson A. A real-time PCR array for hierarchical identification of Francisella isolates. PLoS One. 2009 Dec 21. 4(12):e8360. [Medline]. [Full Text].

  56. Maurin M, Castan B, Roch N, Gestin B, Pelloux I, Mailles A, et al. Real-time PCR for diagnosis of oculoglandular tularemia. Emerg Infect Dis. 2010 Jan. 16(1):152-3. [Medline]. [Full Text].

  57. Johansson A, Berglund L, Eriksson U, et al. Comparative analysis of PCR versus culture for diagnosis of ulceroglandular tularemia. J Clin Microbiol. 2003. 38:22-26.

  58. [Guideline] ASM. Sentinel Level Clinical Laboratory Guidelines for Suspected Agents of Bioterrorism and Emerging Infectious Diseases. asm.org. Available at http://www.asm.org/images/PSAB/LRN/TularemiaNov2015.pdf. 2015 Nov; Accessed: February 27, 2016.

  59. Enderlin G, Morales L, Jacobs RF, Cross JT. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis. 2004. 19:42-7.

  60. Cross JT, Jacobs RF. Tularemia: treatment failures with outpatient use of ceftriaxone. Clin Infect Dis. 1993 Dec. 17(6):976-80. [Medline].

  61. Pérez-Castrillón JL, Bachiller-Luque P, Martín-Luquero M, Mena-Martín FJ, Herreros V. Tularemia epidemic in northwestern Spain: clinical description and therapeutic response. Clin Infect Dis. 2001 Aug 15. 33(4):573-6. [Medline].

  62. Jellison WL. Tularemia: Dr. Edward Francis and his first 23 isolates of Francisella tularensis. Bull Hist Med. 1972 Sep-Oct. 46(5):477-85. [Medline].

  63. McCoy GW, Chapin CW. Further observations on a plague-like disease of rodents with a preliminary note on the causative agent Bacterium tularense. J Infect Dis. 1912. 10:61-72:

  64. McCoy GW. A plague-like disease of rodents. Publ Hlth Bull. 1911. 43:53-71:

  65. Trevisanato SI. The 'Hittite plague', an epidemic of tularemia and the first record of biological warfare. Med Hypotheses. 2007. 69(6):1371-4. [Medline].

  66. Wherry WB, Lamb BH. Infection of man with Bacterium tularense. J Infect Dis. 1941. 15:331-40.

 
Previous
Next
 
Eschar on thumb and under thumbnail at the site of a rabbit bite in a patient with tularemia.
Axillary bubo in a patient with tularemia.
Ulceroglandular type of tularemia on the face. Courtesy of Dr Hon Pak.
Ulceroglandular tularemia on an extremity. Courtesy of Dr Hon Pak.
Ulceroglandular type of tularemia on the hand. Courtesy of Dr Hon Pak.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.